Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer

International Journal of Cancer

Volumn 107, Issue 5, 2003, Pages 781-790

  Pollán, Marina ^a,p   Varela, Gonzalo ^b   Torres, Antonio ^c   De la Torre, Mercedes ^d   Ludeña, Ma Dolores ^b   Ortega, Ma Dolores ^c   Pac, Joaquín ^e   Freixenet, Jorge ^f   Gómez, Guillermo ^g   Sebastián, Fernando ^h   Díez, Manuel ⁱ   Arrabal, Ricardo ^j   Canalís, Emili ^k   García Tirado, Javier ^l   Arnedillo, Aurelio ^m,n   Rivas, Juan José ^l   Minguella, Joan ^o   Gómez, Ana ^c   García, Mauricio ^c   Aragonés, Nuria ^a   Pérez Gómez, Beatriz ^a   López Abente, Gonzalo ^a   González Sarmiento, Rogelio ^o   Rojas, Jose María ^a   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f Hospital Dr Negri   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL JOSEP TRUETA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^j HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^m HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

ⁿ HOSPITAL DEL MAR   (Spain)

^o Centro de Investigacion del Cancer   (Spain)

^p CARLOS III INSTITUTE OF HEALTH   (Spain)

more..

Author keywords

c erbB 2; CA125; CEA; Non small cell lung cancer; p53; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ONCOPROTEIN; PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

ADENOCARCINOMA; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744229249     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11472     Document Type: Article

References (56)

1. Junker K. Prognostic factors in Stage 1/II non-small cell lung cancer. Lung Cancer 2001;33(Suppl):S17-24.
2. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am 1997;11:409-34.
3. Huncharek M, Kupelnick B, Geschwind JF, Caubet JF. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 2000;153:219-26.
4. Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farre G, Labib T, Pottier G, Sesboue R, Bronner C, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000;6:1125-34.
5. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
6. Mountain CF. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest 1995;108:246-54.
7. Niklinski J, Niklinska W, Chyczewski L, Becker HD, Pluygers E. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev 2001;10:213-26.
8. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
9. Hayes DF. Clinical importance of prognostic factors. In: Bronchud MH, Foote MA, Peters WP, Robinson MO, eds. Principles of molecular oncology. Totowa, NJ: Humana Press, 2000. 29-44.
10. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, et al. Tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
11. Travis WD, Colby TV, Corrin B. World Health Organization classification of lung and pleural tumors, 3rd ed. Berlin: Springer-Verlag, 1999.
12. Diez M, Torres A, Maestro ML, Ortega MD, Gomez A, Pollan M, Lopez JA, Picardo A, Hernando F, Balibrea JL. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 1996;73:1248-54.
13. Picardo AL, Diez M, Torres A, Maestro M, Ortega D, Hernando F, Gomez A, Garcia-Asenjo J, Balibrea JL. Analysis of the prognostic significance of cytosotic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma. Cancer 1996;77:1066-72.
14. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982;69:553-66.
15. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest 2000;117:1247-55.
16. Hardin JM, Hilbe J. Generalized linear models and extensions, p. xiv, 245. College Station, TX: Strata Press, 2001.
17. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
18. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625-34.
19. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J. Correlation between the status of the p53 gene and survival in patients with Stage I non-small cell lung carcinoma. Oncogene 1999;18:1007-14.
20. Lindahl T, Norberg T, Aström G, Sjögren S, Bergh CJ. Cellular and tissue markers in solid tumors. In: Bronchud MH, Foote MA, Peters WP, Robinson MO, eds. Principles of molecular oncology. Totowa, NJ: Humana Press, 2000. 95-110.
21. Harpole DH Jr, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in Stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
22. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and Bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997;80:1034-45.
23. Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE, Shieh DB, Richards W, Blanco R, Xu HJ, Strauss GM, Sugarbaker DJ. Molecular Pathologic substaging in 244 Stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77.
24. D'Amico TA, Massey M, Herndon JE, Moore MB, Harpole DH Jr. A biologic risk model for Stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-43.
25. Konishi T, Lin Z, Fujino S, Kato H, Mori A. Association of p53 protein expression in Stage I lung adenocarcinoma with reference to cytological subtypes. Hum Pathol 1997;28:544-8.
26. Levesque MA, D'Costa M, Spratt EH, Yaman MM, Diamandis EP. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. Int J Cancer 1998;79:494-501.
27. Tammemagi MC, McLaughlin JR, Mullen JB, Bull SB, Johnston MR, Tsao MS, Casson AG. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol 2000;10:176-85.
28. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-71.
29. Tanaka F, Takata T, Yamada T, Yanagihara K, Otake Y, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Inui K, Wada H. Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer. Lung Cancer 2002;36:27-32.
30. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-19.
31. Lucchi M, Fontanini G, Mussi A, Vignati S, Ribechini A, Menconi GF, Bevilacqua G, Angeletti CA. Tumor angiogenesis and biologic markers in resected Stage I NSCLC. Eur J Cardiothorac Surg 1997;12:535-41.
32. MacKinnon M, Kerr KM, King G, Kennedy MM, Cockburn JS, Jeffrey RR. P53, c-ErbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. Eur J Cardiothorac Surg 1997;11:838-42.
33. Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB. The interactive effect of ras, HER2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998;22:181-90.
34. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F. Immunocytochemical markers in Stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
35. Komaki R, Milas L, Ro JY, Fujii T, Perkins P, Allen P, Sikes CR, Mountain CF, Ordonez NG. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;40:787-96.
36. Lavezzi AM, Santambrogio L, Bellaviti N, Biondo B, Nosotti M, Radice F, Matturri L. Prognostic significance of different biomarkers in non-small cell lung cancer. Oncol Rep 1999;6:819-25.
37. Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, Bucciarelli E, Darwish S, Ludovini V, Pistola L, Gregorc V, Tonato M. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000;74:53-60.
38. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH. Lack of prognostic significance of p53 and k-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2001;19:448-57.
39. Komiya T, Hirashima T, Kawase I. Clinical significance of p53 in non-small-cell lung cancer. Oncol Rep 1999;6:19-28.
40. You XL, Yen L, Zeng-Rong N, Al Moustafa AE, Alaoui-Jamali MA. Dual effect of ErbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. Oncogene 1998;17:3177-86.
41. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-ErbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;27:1372-5.
42. Diez M, Pollan M, Maestro M, Torres A, Ortega D, Gomez A, Sanchez A, Hernando F, Balibrea JL. Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue. Br J Cancer 1997;75:684-9.
43. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, Harris AL. Bcl-2 and c-ErbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 1999;17:545-54.
44. Giatromanolaki A, Gorgoulis V, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC, Iordanoglou I. c-ErbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 1996;16:987-93.
45. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA Jr. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-56.
46. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996;74:86-91.
47. Buccheri G, Ferrigno D. Lung tumor markers in oncology practice: a study of TPA and CA125. Br J Cancer 2002;87:1112-8.
48. Suzuki K, Nagai K, Yoshida J, Moriyama E, Nishimura M, Takahashi K, Nishiwaki Y. Prognostic factors in clinical Stage I non-small cell lung cancer. Ann Thorac Surg 1999;67:927-32.
49. Salgia R, Harpole D, Herndon JE, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res 2001;21:1241-6.
50. Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 2001;44:180-8.
51. Molina R, Filella X, Jo J, Agusti C, Ballesta AM. CA125 in biological fluids. Int J Biol Markers 1998;13:224-30.
52. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002;69:25-9.
53. Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T. Optimal combination of seven tumor markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 2001;21:3085-92.
54. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer 1993;10:21-33.
55. Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, Barak V. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999;19:3549-52.
56. Pina TC, Zapata IT, Lopez JB, Perez JL, Paricio PP, Hernandez PM. Tumor markers in lung cancer: does the method of obtaining the cut-off point and reference population influence diagnostic yield? Clin Biochem 1999;32:467-72.